Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127901571 | 12790157 | 1 | I | 20160426 | 20160923 | 20160928 | 20160928 | EXP | FR-AFSSAPS-TO20161922 | FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-62467FF | BOEHRINGER INGELHEIM | 72.77 | YR | M | Y | 0.00000 | 20160928 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127901571 | 12790157 | 1 | PS | VIRAMUNE | NEVIRAPINE | 1 | Oral | 400 MG | 201152 | 400 | MG | PROLONGED-RELEASE TABLET | QD | ||||||
| 127901571 | 12790157 | 2 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | DOSE PER APPLICATION AND DAILY DOSE: 200MG/245MG | Y | 0 | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127901571 | 12790157 | 1 | HIV infection |
| 127901571 | 12790157 | 2 | HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127901571 | 12790157 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127901571 | 12790157 | Renal disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127901571 | 12790157 | 1 | 20150317 | 0 | ||
| 127901571 | 12790157 | 2 | 20150317 | 20160426 | 0 |